Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy

被引:26
|
作者
De, Brian [1 ]
Ng, Sweet Ping [1 ,2 ]
Liu, Amy Y. [1 ]
Avila, Santiago [1 ]
Tao, Randa [3 ]
Holliday, Emma B. [1 ]
Brownlee, Zachary [4 ]
Kaseb, Ahmed [5 ]
Lee, Sunyoung [3 ]
Raghav, Kanwal [5 ]
Vauthey, Jean-Nicolas [6 ]
Minsky, Bruce D. [1 ]
Herman, Joseph M. [1 ]
Das, Prajnan [1 ]
Smith, Grace L. [1 ]
Taniguchi, Cullen M. [1 ]
Krishnan, Sunil [7 ]
Crane, Christopher H. [8 ]
Grassberger, Clemens [9 ]
Hong, Theodore S. [9 ]
Lin, Steven H. [1 ]
Koong, Albert C. [1 ]
Mohan, Radhe [1 ]
Koay, Eugene J. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX USA
[2] Dept Radiat Oncol, Austin Hlth, Melbourne, Vic, Australia
[3] Univ Utah, Dept Radiat Oncol, Huntsman Canc Inst, Salt Lake City, UT USA
[4] Tufts Med Ctr, Dept Radiat Oncol, Boston, MA USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX USA
[7] Mayo Clin Jacksonville, Dept Radiat Oncol, Jacksonville, FL USA
[8] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA
[9] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA
基金
美国国家卫生研究院;
关键词
lymphocyte count; circulating lymphocytes; splenic dose; liver dose; overall survival; PROTON-BEAM THERAPY; SURVIVAL; CANCER; CHEMORADIOTHERAPY; PROGNOSIS;
D O I
10.2147/JHC.S282062
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The immune system plays a crucial role in cancer surveillance. Previous studies have shown that lymphopenia associated with radiotherapy (RT) portends a poor prognosis. We sought to differentiate the effects of proton and photon RT on changes in absolute lymphocyte count (ALC) for patients with hepatocellular carcinoma (HCC). Patients and Methods: Patients with HCC treated with definitive RT from 2006 to 2016 were studied. Serial ALCs were graded according to CTCAE v4.0. Overall survival (OS), disease-free survival, and distant metastasis-free survival were analyzed using the Kaplan-Meier method. Univariable and multivariable Cox-proportional hazards analyses were used to identify predictors of OS. A cohort analysis matched for treatment volume was performed to investigate differences in ALC dynamics between photon and proton therapy. Results: Of 143 patients identified, the median age was 66 (range, 19-90) years. The treatment modality was photon in 103 (72%) and proton in 40 (28%). Median follow-up was 17 months (95% confidence interval, 13-25 months). The median time to ALC nadir after initiation of RT was 17 days with a median relative decrease of 67%. Those who received proton RT had a higher median ALC nadir (0.41 vs 0.32 k/mu L, p=0.002) and longer median OS (33 vs 13 months, p=0.002) than those who received photon RT. Matched cohort analyses revealed a larger low-dose liver volume in the photon group, which correlated with lower ALC. On multivariable Cox analysis, Grade 3 or higher lymphopenia prior to or after RT, portal venous tumor thrombus, larger planning target volumes, Child-Pugh (CP) Class B, and increased CP score after RT were associated with a higher risk of death, whereas the use of proton therapy was associated with lower risk. Conclusion: Grade 3 or higher lymphopenia may be associated with poorer outcomes in patients receiving RT for HCC. Protons may mitigate lymphopenia compared with photons, potentially due to reduced dose exposure of sites of lymphopoiesis.
引用
收藏
页码:57 / 69
页数:13
相关论文
共 50 条
  • [31] Combination of Sorafenib and Intensity Modulated Radiotherapy for Unresectable Hepatocellular Carcinoma
    Hsieh, Chen-Hsi
    Jeng, Kuo-Shyang
    Lin, Ching-Chung
    Chen, Chi-Kuan
    Liu, Chia-Yuan
    Lin, Chin-Ping
    Tai, Hung-Chi
    Wang, Chao-Hsing
    Shueng, Pei-Wei
    Chen, Yu-Jen
    CLINICAL DRUG INVESTIGATION, 2009, 29 (01) : 65 - 71
  • [32] Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis
    Tada, Toshifumi
    Kumada, Takashi
    Hiraoka, Atsushi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Shimada, Noritomo
    Kawata, Kazuhito
    Tanaka, Takaaki
    Ohama, Hideko
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Naganuma, Atsushi
    Aoki, Tomoko
    Koizumi, Yohei
    Nakamura, Shinichiro
    Joko, Kouji
    Hiasa, Yoichi
    Kudo, Masatoshi
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 34 (08) : 857 - 864
  • [33] Effect of Handgrip Strength on Clinical Outcomes of Patients with Hepatocellular Carcinoma Treated with Lenvatinib
    Kotoh, Yurika
    Saeki, Issei
    Yamasaki, Takahiro
    Sasaki, Ryo
    Tanabe, Norikazu
    Oono, Takashi
    Matsuda, Takashi
    Hisanaga, Takuro
    Matsumoto, Toshihiko
    Hidaka, Isao
    Ishikawa, Tsuyoshi
    Takami, Taro
    Sakaida, Isao
    APPLIED SCIENCES-BASEL, 2020, 10 (16):
  • [34] Higher radiation dose on immune cells is associated with radiation-induced lymphopenia and worse prognosis in patients with locally advanced esophageal squamous cell carcinoma
    Qiu, Jianjian
    Lin, Hancui
    Ke, Dongmei
    Yu, Yilin
    Xu, Jiaying
    Qiu, Hejin
    Zheng, Qunhao
    Li, Hui
    Zheng, Hongying
    Liu, Lingyun
    Wang, Zhiping
    Yao, Qiwei
    Li, Jiancheng
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [35] Hypofractionated Radiotherapy-Related Lymphopenia Is Associated With Worse Survival in Unresectable Intrahepatic Cholangiocarcinoma
    Lee, Grace
    Kim, Daniel W.
    Smart, Alicia C.
    Horick, Nora K.
    Eyler, Christine E.
    Roberts, Hannah J.
    Pathak, Priyadarshini
    Goyal, Lipika
    Franses, Joseph
    Heather, James M.
    Hwang, William L.
    Grassberger, Clemens
    Klempner, Samuel J.
    Drapek, Lorraine C.
    Allen, Jill N.
    Blaszkowsky, Lawrence S.
    Parikh, Aparna R.
    Ryan, David P.
    Clark, Jeffrey W.
    Hong, Theodore S.
    Wo, Jennifer Y.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (08): : 373 - 382
  • [36] Effect of Body Composition on Outcomes in Patients with Hepatocellular Carcinoma Undergoing Radiotherapy: A Retrospective Study
    Li, Li-Qing
    Zhao, Wei-Dong
    Su, Ting-Shi
    Wang, Yu-Dan
    Meng, Wan-Wan
    Liang, Shi-Xiong
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2022, 74 (09): : 3302 - 3311
  • [37] Transarterial Chemoembolization Followed by Radiotherapy Versus Sandwich Treatment for Unresectable or Ablative Hepatocellular Carcinoma
    Lin, Haimin
    Wu, Huiyong
    Cong, Ning
    Liu, Bo
    Liu, Chengxin
    Han, Dali
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2020, 19
  • [38] Causes of death in patients with unresectable hepatocellular carcinoma
    Couto, O. F. M.
    Dvorchik, I.
    Carr, B. I.
    DIGESTIVE DISEASES AND SCIENCES, 2007, 52 (11) : 3285 - 3289
  • [39] Causes of Death in Patients with Unresectable Hepatocellular Carcinoma
    O. F. M. Couto
    I. Dvorchik
    B. I. Carr
    Digestive Diseases and Sciences, 2007, 52 : 3285 - 3289
  • [40] FDG-PET predicts outcomes of treated bone metastasis following palliative radiotherapy in patients with hepatocellular carcinoma
    Choi, Seo Hee
    Chang, Jee Suk
    Jeong, Yong Hyu
    Lee, Youngin
    Yun, Mijin
    Seong, Jinsil
    LIVER INTERNATIONAL, 2014, 34 (07) : 1118 - 1125